Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents. / Nushtaeva, Anna A.; Stepanov, Grigory A.; Semenov, Dmitry V. и др.
в: BMC Cancer, Том 18, № 1, 728, 09.07.2018, стр. 728.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents
AU - Nushtaeva, Anna A.
AU - Stepanov, Grigory A.
AU - Semenov, Dmitry V.
AU - Juravlev, Evgeny S.
AU - Balahonova, Evgenia A.
AU - Gerasimov, Alexey V.
AU - Sidorov, Sergey V.
AU - Savelyev, Eugeniy I.
AU - Kuligina, Elena V.
AU - Richter, Vladimir A.
AU - Koval, Olga A.
N1 - Publisher Copyright: © 2018 The Author(s).
PY - 2018/7/9
Y1 - 2018/7/9
N2 - Background: The phenomenon of chemotherapy-resistant cancers has necessitated the development of new therapeutics as well as the identification of specific prognostic markers to predict the response to novel drugs. Primary cancer cells provide a model to study the multiplicity of tumourigenic transformation, to investigate alterations of the cellular response to various molecular stimuli, and to test therapeutics for cancer treatment. Methods: Here, we developed primary cultures of human breast tissue - normal cells (BN1), cancer cells (BC5), and cells from a chemotherapy-treated tumour (BrCCh1) to compare their response to conventional chemotherapeutics and to innate immunity stimulators with that of the immortalized breast cells MCF7, MDA-MB-231, and MCF10A. Expression of the progesterone receptor (PGR), oestrogen receptor (ER) α and β, human epidermal growth factor receptor (HER) 2 and 3 and aromatase CYP19, as well as expression of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) mRNA in human breast cells were characterized. Results: We revealed that BC5 carcinoma cells were PGRlow/ERbhigh/ERa-/Cyp19+, the BrCCh1 cells that originated from the recurrent tumour were PGR-/ERb+/ERa-/Cyp19+, and normal BN cells were PGR-/ERb+/ERa-/Cyp19high. The treatment of primary culture cells with antitumour therapeutics revealed that BrCCh1 cells were doxorubicine-resistant and sensitive to cisplatin. BC5 cells exhibited low sensitivity to tamoxifen and cisplatin. The innate immunity activators interferon-α and an artificial small nucleolar RNA analogue increased expression of IFIT3 at different levels in primary cells and in the immortalized breast cells MCF7, MDA-MB-231, and MCF10A. The relative level of activation of IFIT3 expression was inversely correlated with the baseline level of IFIT3 mRNA expression in breast cell lines. Conclusion: Our data demonstrated that primary cancer cells are a useful model for the development of novel cancer treatments. Our findings suggest that expression of IFIT3 mRNA can be used as a prognostic marker of breast cancer cell sensitivity to immunostimulating therapeutics.
AB - Background: The phenomenon of chemotherapy-resistant cancers has necessitated the development of new therapeutics as well as the identification of specific prognostic markers to predict the response to novel drugs. Primary cancer cells provide a model to study the multiplicity of tumourigenic transformation, to investigate alterations of the cellular response to various molecular stimuli, and to test therapeutics for cancer treatment. Methods: Here, we developed primary cultures of human breast tissue - normal cells (BN1), cancer cells (BC5), and cells from a chemotherapy-treated tumour (BrCCh1) to compare their response to conventional chemotherapeutics and to innate immunity stimulators with that of the immortalized breast cells MCF7, MDA-MB-231, and MCF10A. Expression of the progesterone receptor (PGR), oestrogen receptor (ER) α and β, human epidermal growth factor receptor (HER) 2 and 3 and aromatase CYP19, as well as expression of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) mRNA in human breast cells were characterized. Results: We revealed that BC5 carcinoma cells were PGRlow/ERbhigh/ERa-/Cyp19+, the BrCCh1 cells that originated from the recurrent tumour were PGR-/ERb+/ERa-/Cyp19+, and normal BN cells were PGR-/ERb+/ERa-/Cyp19high. The treatment of primary culture cells with antitumour therapeutics revealed that BrCCh1 cells were doxorubicine-resistant and sensitive to cisplatin. BC5 cells exhibited low sensitivity to tamoxifen and cisplatin. The innate immunity activators interferon-α and an artificial small nucleolar RNA analogue increased expression of IFIT3 at different levels in primary cells and in the immortalized breast cells MCF7, MDA-MB-231, and MCF10A. The relative level of activation of IFIT3 expression was inversely correlated with the baseline level of IFIT3 mRNA expression in breast cell lines. Conclusion: Our data demonstrated that primary cancer cells are a useful model for the development of novel cancer treatments. Our findings suggest that expression of IFIT3 mRNA can be used as a prognostic marker of breast cancer cell sensitivity to immunostimulating therapeutics.
KW - Breast cancer
KW - Cancer stem cells
KW - CD24
KW - CD44
KW - Hormone receptor
KW - IFIT3
KW - Interferon-α
KW - Primary culture
KW - Prognostic marker
KW - SnoRNA
KW - Hyaluronan Receptors/analysis
KW - CD24 Antigen/analysis
KW - Humans
KW - Receptors, Estrogen/analysis
KW - Adjuvants, Immunologic/therapeutic use
KW - Intracellular Signaling Peptides and Proteins/genetics
KW - Cell Line, Tumor
KW - Female
KW - RNA, Messenger/analysis
KW - Breast Neoplasms/chemistry
KW - MOLECULAR SUBTYPES
KW - ACTIVATION
KW - SENSITIVITY
KW - HEPATOCELLULAR-CARCINOMA
KW - Interferon-alpha
KW - ADENOCARCINOMA
KW - QUANTIFICATION
KW - PHENOTYPE
KW - snoRNA
KW - EPITHELIAL-MESENCHYMAL TRANSITION
KW - STEM-CELL
KW - PERSONALIZED-MEDICINE
UR - http://www.scopus.com/inward/record.url?scp=85049793867&partnerID=8YFLogxK
U2 - 10.1186/s12885-018-4635-8
DO - 10.1186/s12885-018-4635-8
M3 - Article
C2 - 29986702
AN - SCOPUS:85049793867
VL - 18
SP - 728
JO - BMC Cancer
JF - BMC Cancer
SN - 1471-2407
IS - 1
M1 - 728
ER -
ID: 17862356